Overview

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-11-15
Target enrollment:
Participant gender:
Summary
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.
Phase:
Phase 1
Details
Lead Sponsor:
ADC Therapeutics S.A.
Treatments:
Pembrolizumab